Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
28.01%
Net Margin
19.38%
Efficiency Metrics
Revenue per Expense Ratio
1.00
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
28.04%
Income Tax Rate
20.50%
EPS
3.2700000000
Balance Sheet Analysis
Current Ratio
61,139,000,000.0
Cash Ratio
130,632,000,000.0
Working Capital
$61.14B
Debt to Equity
1.14
Debt to Assets
9.49%
Equity Ratio
8.34%
Cash Flow Analysis
Operating Cash Flow Ratio
30.15%
Free Cash Flow Ratio
51.67%
CapEx to Revenue
21.51%
Dividends Paid
$3.31B
Stock Buybacks
$62.00M
Total Shareholder Returns
$3.37B
Cash Position Change
14.29%
Key Takeaways (2023 FY)
Increased dividend payments by 3.91%
Detailed Growth Metrics
Core Performance
Revenue
15.83%
Net Income
-6.80%
EPS
-11.38%
Operating Income
-25.31%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
15.91%
Operating Cash Flow
-60.00%
Free Cash Flow
-60.00%
Balance Sheet Health
Assets
-1.68%
Debt
-11.42%
Book Value per Share
5.05%
Inventory
100.00%
Shareholder Returns
Dividends per Share
3.91%
Shares Outstanding
3.63%
Long Term Trends
3Y Revenue/Share
17.95%
5Y Revenue/Share
31.72%
3Y Dividend/Share
13.54%
5Y Dividend/Share
48.19%